What is the incremental cost-effectiveness ratio (ICER)? Posted 03/12/2010
The incremental cost-effectiveness ratio (ICER) often comes up when talking about drug comparisons, but what is it and how does it relate to medicines?
A health economic evaluation involves a comparative analysis where a therapeutic intervention is compared to another health technology. The results of this analysis are expressed by means of an incremental cost-effectiveness ratio (ICER), which is defined as the ratio of the change in costs of a therapeutic intervention (compared to the alternative, such as doing nothing or using the best available alternative treatment) to the change in effects of the intervention. Incremental cost-effectiveness ratio (ICER) = (C1 – C0) / (E1 – E0) Where C1 is the cost of the medicine; C0 is the cost of the comparator technology; E1 and E0 are the consequences of the medicine and the comparator, respectively. The change in effects is usually measured in terms of the number of life-years gained or quality-adjusted life years gained by the intervention. Related article Market access for biopharmaceuticals and biosimilars: a case study
Source: Steven Simoens. Personal Communication. 30 September 2010.
Comments (0)
Generics News Research General
- Lipitor generics saved UK NHS £350 million in f...Generics/General | Posted 31/05/2013
- Teva and Sun Pharma settle battle over generic...Generics/News | Posted 14/06/2013
- Dr Reddy’s and Fujifilm call off joint venture...Generics/News | Posted 07/06/2013
- US appeals court halts Pulmicort genericsGenerics/News | Posted 31/05/2013
Biosimilars News Research General
- Use of G-CSF biosimilars for reduction of feverBiosimilars/Research | Posted 14/06/2013
- Call for clarity in FDA’s draft guidance on bio...Biosimilars/General | Posted 14/06/2013
- Positive post-marketing data for biosimilar epo...Biosimilars/Research | Posted 07/06/2013
- Use of G-CSF biosimilars for stem cell mobiliza...Biosimilars/Research | Posted 07/06/2013




